tients with these deep-seated lesions. 1, 18, 19, 25, 33, 35 The goal of SRS is complete obliteration of the AVM nidus while avoiding postprocedural ARE. Total obliteration rates after a single procedure vary between 60% and 80% over a 5-year period. 1, 7, 18, 19, 25, 33, 35 Patients remain at risk for hemorrhage during the latency interval between SRS and obliteration.
In this article we describe the outcomes of patients with AVMs of the basal ganglia and thalamus. All patients underwent SRS at a single institution over a 20-year period. We reviewed factors associated with total obliteration, risk of hemorrhage, and complications.
Methods

Patient Population
Between August 1987 and December 2006, 996 patients with AVM underwent single-stage SRS in which the Leksell Gamma Knife (Elekta AB) was used at our center. Fifty-six patients had AVMs of the basal ganglia (defined as the putamen and the globus pallidus) and 77 had AVMs of the thalamus. The series included 70 male and 63 female patients, whose median age was 26 years (range 3-69 years). Twenty patients underwent prior partial AVM resection and 18 patients underwent prior embolization. Symptoms leading to the diagnosis were hemorrhage in 113 patients (85%), seizures in 3 (2%), headaches in 13 (10%), limb incoordination in 1 (0.8%), and hand intention tremor in 1 (0.8%). Three patients (2%) were diagnosed by imaging during an evaluation of a complaint unrelated to the AVM. The University of Pittsburgh's institutional review board approved this retrospective study.
The demographics and AVM characteristics are shown in Table 1 . Eleven patients (8%) had a venous outflow varix and 7 (5%) had a coexisting arterial aneurysm. A Spetzler-Martin Grade II AVM was diagnosed in 11 (8%), Grade III in 48 (36%), Grade IV in 20 (15%), and Grade VI in 54 patients (41%). 37 The modified PollockFlickinger AVM grading system was also used. 31, 40 The equation used to calculate the modified Pollock-Flickinger AVM grading score is as follows: Score = (0.1) (volume in cm 3 ) + (0.02) (age in years) + (0.5) (location: basal ganglia, thalamus, or brainstem = 1, others = 0). The modified Pollock-Flickinger AVM scores are shown in Table 1 . The outcome data were collected by 3 neurosurgeons (H.K., H.Y., and T.J.F.) who had not participated in the initial patient management. Outcome data were obtained from review of each patient's medical record and supplemented by telephone discussions with the patient and/or patient's family and current treating physicians. The Spetzler-Martin grades and pertinent features of the AVM angioarchitecture were determined by 2 experienced neurosurgeons (L.D.L. and D.K.) who had participated in patient management. Follow-up imaging data and complications were interpreted by 2 neurosurgeons (L.D.L. and D.K.) and 1 radiation oncologist (J.C.F.) during reviews performed at our multidisciplinary vascular malformation conference. The modified Pollock-Flickinger AVM scores were calculated by the first author (H.K.), who had not participated in patient management.
Radiosurgery Technique
Our radiosurgical technique has been described in detail in previous reports. 21, 22, 32 In brief, patients more than 13 years of age underwent application of an imaging compatible stereotactic head frame; a local anesthetic was supplemented by intravenous sedation. Younger children underwent the procedure after induction of general endotracheal anesthesia. High-resolution axial imaging (MR imaging after 1991) coupled with biplanar stereotactic angiography was performed for dose planning. The margin SRS dose included the entire AVM nidus volume, defined as the shunt between the afferent arteries and the draining veins. Radiosurgery was performed using a Model U, B, C, or 4-C Leksell Gamma Knife (Elekta AB). All patients received an intravenous dose of 20-40 mg methylprednisolone after radiosurgery and all were discharged from the hospital 2-24 hours after the procedure.
The median maximal diameter of the AVM nidus was 2.0 cm (range 0.6-4.8 cm); the median target volume was 2.7 cm 3 (range 0.1-20.7 cm 3 ); the median prescription dose delivered to the nidus margin was 20 Gy (range 15-25 Gy); the median maximum dose was 38 Gy (range 22.2-50 Gy); and the median number of isocenters was 3 (range 1-12) ( Table 2) .
Patient Follow-Up
After radiosurgery, patients were instructed to undergo clinical and imaging assessments at 6, 12, 24, and 36 months after SRS. If at the end of 3 years MR imag- ing suggested complete obliteration, then repeat angiography was performed. If MR imaging clearly defined a residual nidus, angiography was delayed, and the patient was offered repeat radiosurgery to achieve final AVM obliteration. When MR imaging suggested obliteration of the AVM, cerebral angiography was requested to confirm obliteration.
Complete angiographically documented AVM obliteration was defined as the disappearance of the nidus and absence of early venous drainage. At any time when a new neurological symptom or sign developed, the patient underwent CT and/or MR imaging to rule out hemorrhage or AREs.
Statistical Analysis
We calculated obliteration rates only for initial radiosurgery, with follow-up censored at the time of any retreatment. Actuarial analysis with the end point of AVM obliteration differs from survival analysis by requiring greater care to avoid potential bias. While dates of death are narrowly defined for a survival analysis, AVM obliteration is evaluated by angiography or MR imaging at a discrete time. The exact time of AVM obliteration is not known. In some asymptomatic cases, the patient did not undergo follow-up imaging in the 2-to 5-year period after radiosurgery, although we eventually obtained delayed angiographic studies during the 5-to 10-year period. In such cases, the actual time of AVM obliteration is unknown but likely occurred earlier than 5-10 years posttreatment. In addition, patients with confirmed residual AVMs at 3-4 years routinely underwent repeat radiosurgery at that time. The combined effects of removing patients from the follow-up group when they are re-treated after 3-4 years and the "delayed follow-up" of patients with AVMs (those having confirmatory imaging at periods well beyond 3-4 years) could artificially elevate 10-year actuarial obliteration rate calculations. We therefore defined the estimated or corrected obliteration time as the half-way point between the time that the last MR image showed a patent nidus and the date that an angiogram or MR image documented obliteration. To account for the 97% reliability of MR imaging in establishing AVM obliteration, the following correction factor (mrCF) was applied to the combined obliteration rates documented by either MR imaging (78 cases) or angiography (63 cases): mrCF = 1.0 -0.03 × MR obliterations/(MR obliterations + angiographic obliterations) = 0.983.
We identified a second potential statistical bias in calculating obliteration rates using angiography alone as opposed to defining it with either MR or angiography. While angiography is the gold standard for obliteration, Pollock et al. 34 reported that only 3 of 100 patients with MR imaging-defined obliterations undergoing angiography had a residual nidus. In the present series approximately 60% of the patients did not undergo angiography shortly after their follow-up MR study revealed obliteration. In contrast, almost all patients with an MR imaging-defined residual nidus underwent angiography, often followed by repeat radiosurgery. This artifact of patient management leads to a significant proportion of patients with unobliterated AVMs undergoing angiography. Although we agree that angiography remains the best measure by which to define AVM obliteration, MR imaging remains highly accurate because angiography confirms MR imaging-suggested obliteration in 97% of cases. Using this scenario, the calculated obliteration rates would vary no more than 1%-2% beyond the obliteration rate calculated in patients who undergo both MR imaging and confirmatory angiography.
Kaplan-Meier survival analysis was carried out to calculate rates of hemorrhage and obliteration. In the assessment of hemorrhage, patients were censored on loss of follow-up or at the time of hemorrhage. As such, rates of hemorrhage reflect a single hemorrhage experienced by a patient even if he or she had multiple hemorrhages. Annual hemorrhage rates were calculated based on years of follow-up and total number of hemorrhages; as such, this accounts for the total number of hemorrhages experienced by patients. The log-rank test was used to assess differences in survival curves and Cox regression was used to assess hazard ratios in multivariate analysis. Relevant factors affecting total AVM obliteration and hemorrhage risks after SRS included the following: age, sex, AVM location (thalamus vs basal ganglia), target volume (continuous number, < 3 cm 3 vs ≥ 3 cm 3 and < 6 cm 3 vs ≥ 6 cm 3 ), maximum diameter (continuous number, ≥ 2 cm vs < 2 cm and ≥ 3 cm vs < 3 cm), margin dose (continuous number, ≥ 18 Gy vs < 18 Gy and ≥ 20 Gy vs < 20 Gy), number of isocenters, presence of a varix, presence of a coexisting arterial (not intranidal) aneurysm, number of prior hemorrhages before SRS, number of prior embolization procedures, Spetzler-Martin grade, and the modified Pollock-Flickinger score. In each continuous variable using the log-rank test, we analyzed various cut points to determine a statistically meaningful cut point. In the multivariate analysis using the Cox proportional hazards model, we analyzed variables including age, location, target volume, maximum diameter, margin dose, coexisting aneurysm, and history of prior bleeding. The Mann-Whitney U-test was used to evaluate the relationship between AREs and the risk of delayed cyst formation after SRS. We also evaluated the risk of AREs related to the following variables: age, sex, location, target volume, 12-Gy volume, margin dose, presence of varix, coexistence of an aneurysm, prior hemorrhage, Spetzler-Martin grade, and Pollock-Flickinger score. A value of p < 0.05 was used for statistical significance.
Results
At the time of assessment, 122 patients were alive and 11 had died. Seven patients died due to AVM hemorrhage and 4 patients died of other causes (leukemia, myocardial infarction, pneumonia, and undetermined cause in 1 patient each). After SRS, the median imaging follow-up period was 61 months and the median clinical follow-up period was 81 months (range 2-265 months). All living patients had a minimum imaging and clinical follow-up duration of 1 year.
Total Obliteration Rate After SRS
Postradiosurgery obliteration rates based on either angiography or MR imaging criteria were 57%, 70%, 72%, and 72% at 3, 4, 5, and 10 years, respectively. The median time until MR imaging documentation of total obliteration was 31 months (95% CI 25.85-36.55 months). Applying a correction factor that assumes MR imaging is 97% accurate in assessing obliteration gives 3-, 4-, 5-, and 10-year corrected MR or angiography obliteration rates of 56%, 69%, 71%, and 71%, respectively. Figure 1 also shows the effect of assuming that obliteration occurred only at the time that angiography was performed. The obliteration probability calculated with those uncorrected obliteration times is slightly lower at 3, 4, and 5 years (50%, 65%, and 72% vs 57%, 70%, and 72% with corrected calculations) but higher at 10 years (76% vs 72% with correction). The actuarial total obliteration rates based on angiography alone were 47%, 60%, 63%, and 63% at 3, 4, 5, and 10 years, respectively at a median of 36.7 months (95% CI 29.19-44.21 months) with corrected obliteration times. Any obliteration rates calculated by angiography alone from this series are biased (artificially lowered) by exclusion of patients with MR imaging-defined obliteration who declined angiography.
In the univariate analysis, factors associated with a higher rate of total obliteration on MR imaging included basal ganglia location (p = 0.026), smaller target volume (continuous number, p = 0.002, < 3 cm 3 , p = 0.001; and < 6 cm 3 , p = 0.008), smaller maximum diameter (continuous number, p < 0.0005; < 2 cm, p = 0.001; and < 3 cm, p = 0.020), higher margin dose (continuous number, p = 0.002, > 18 Gy, p = 0.012; and ≥ 20 Gy, p = 0.007), and smaller number of isocenters (p = 0.009) ( Table 3) . Factors associated with a higher rate of total obliteration on angiography included smaller target volume (continuous number, p = 0.005; < 3 cm (Table 3 ). In the multivariate analysis, factors associated with a higher MR imaging total obliteration rate were higher margin dose (HR 1.122, 95% CI 1.049-1.200; p = 0.001) and basal ganglia location (HR 1.808, 95% CI 1.154-2.832; p = 0.010). In the multivariate analysis, factors associated with higher angiographically confirmed obliteration rates included: higher margin dose (HR 1.130, 95% CI 1.047-1.219; p = 0.002), basal ganglia location (HR 1.651, 95% CI 1.000-2.727; p = 0.050), and prior hemorrhage (HR 2.748, 95% CI 1.083-6.970; p = 0.033) ( Table 4) .
The actual rate of total obliteration on MR imaging or angiography in AVMs treated with a margin dose of 20 Gy or more (89 lesions) was 65%, 74%, and 77% at 3, 4, and 5 years, respectively. The median time to confirmed complete angiography obliteration was 36.1 months. For AVMs treated with margin doses less than 20 Gy (44 cases), total obliteration after a single SRS was 40%, 60%, and 60% at 3, 4, and 5 years, respectively. A margin dose of 20 Gy or more was associated with a higher rate of total obliteration (p = 0.007) (Fig. 2 ).
Hemorrhage After Radiosurgery
Fifteen patients (11%) suffered a single AVM hemorrhage at a median of 24 months (range 3-118 months) after SRS. Two of 15 had an additional hemorrhage. One of these 2 patients who had an additional hemorrhage died 2 months after SRS. Six patients died after a single AVM hemor- rhage at a median of 23 months (range 2.3-35.7 months) after SRS (mortality rate 5.3%). In 364.4 patient-years of estimated hemorrhage risk (the interval from the date of SRS to the date of total obliteration on angiography or the date of last follow-up imaging showing a residual AVM), we confirmed 17 hemorrhages, which corresponds to an annual hemorrhage rate of 4.7%. In the 1st (126.6 patientyears with 133 patients), 2nd (95.8 patient-years with 118 patients), and 3rd (55.6 patient-years with 76 patients) years after SRS, 8, 2, and 3 hemorrhages occurred, respectively. The annual hemorrhage rates of Years 1, 2, and 3 after SRS were 6.3%, 2.1%, and 5.3%, respectively. The hemorrhage rate after SRS was 4.5%, 6.2%, 9.0%, 11.2%, and 15.4% at Upper: Kaplan-Meier curves of total obliteration on MR imaging or angiography after SRS for AVMs of the basal ganglia and thalamus comparing 2 margin doses (≥ 20 Gy and < 20 Gy). A margin dose of ≥ 20 Gy was significantly associated with a higher total obliteration rate on MR imaging or angiography (p = 0.007). Lower: Kaplan-Meier curves of total obliteration on angiography alone after SRS for AVMs of the basal ganglia and thalamus comparing 2 target volumes (≥ 6 cm 3 and < 6 cm 3 ). A target volume of < 6 cm 3 was significantly associated with a higher total obliteration rate on MR imaging or angiography (p = 0.008).
1, 2, 3, 5, and 10 years, respectively (Fig. 3) . No patient bled after MR imaging or angiographic documentation of AVM obliteration.
In the univariate analysis, factors associated with an increased hemorrhage rate after SRS included a larger target volume (continuous number, p < 0.0005; ≥ 6 cm 3 , p = 0.012), maximum diameter (continuous, p < 0.0005; ≥ 3 cm, p = 0.002), lower margin dose (continuous number, p = 0.012; > 18 Gy, p = 0.008; and ≥ 20 Gy, p = 0.023), larger number of isocenters (p = 0.001), and lower Pollock-Flickinger score (p = 0.003) ( Table 3 ). In multivariate analyses, larger target volume was associated with a higher rate of hemorrhage after SRS (HR 1.164, 95% CI 1.070-1.266; p < 0.0005). Other variables, including margin dose, presence of a varix, presence of a coexisting aneurysm, prior hemorrhage, and prior embolization, did not increase the risk of hemorrhage after SRS ( Table 4 ).
The rate of AVM hemorrhage after SRS in AVMs 6 cm 3 or greater in size was 7.1%, 11.0%, 23.2%, 28.0%, and 28.0% at 1, 2, 3, 5, and 10 years, respectively. The rate of AVM bleeding after SRS in lesions smaller than 6 cm 3 was 3.8%, 4.8%, 4.8%, 6.3%, and 12.0% at 1, 2, 3, 5, and 10 years, respectively. A nidus volume of 6 cm 3 or greater was associated with an increased bleeding risk after SRS (p = 0.012) (Fig. 3) .
When 5 patients with 7 hemorrhages occurring within the first 6 months of SRS were removed from this analysis, the annual hemorrhage rate was 2.7%. The cumulative hemorrhage rate after SRS was 0.8%, 2.5%, 5.4%, 7.7%, and 12.1% at 1, 2, 3, 5, and 10 years, respectively.
Adverse Radiation Effects
In 13 patients (9.8%), symptomatic AREs developed after SRS at a median of 13.2 months (range 5.8-58.3 months). In 6 patients (4.5%), a persistent hemiparesis developed. In 7 patients with a transient hemiparesis, the symptoms were successfully managed with a short course of oral corticosteroids. Factors associated with a higher rate of symptomatic AREs included AVM location in the thalamus (p = 0.041), larger volume AVMs (p < 0.0005), larger 12-Gy treatment volume (p = 0.001), larger maximum diameter (p < 0.0005), higher margin dose (p = 0.016), margin dose > 18 Gy (p = 0.007), margin dose > 20 Gy (p = 0.022), larger number of isocenters (p = 0.022), and higher Pollock-Flickinger score (p = 0.008) ( Table 5 ). Other variables, including age, sex, SpetzlerMartin grade, prior hemorrhage, and prior embolization, were not associated with a risk of developing symptomatic AREs. In 1 patient (0.7%) with a prior thalamic hem- Fig. 3 . Upper: Kaplan-Meier curves of hemorrhage rate after SRS for AVMs of the basal ganglia and thalamus. Lower: Kaplan-Meier curves of hemorrhage rate after SRS for AVMs of the basal ganglia and thalamus comparing 2 target volumes (≥ 6 cm 3 and < 6 cm 3 ). A target volume of < 6 cm 3 was significantly associated with a higher bleeding rate (p = 0.012). orrhage, delayed cyst development was diagnosed at 56 months after SRS but required no additional treatment.
Additional Management
Eighteen patients with still-patent AVMs underwent a second SRS at a median of 45 months (range 24-126 months) after the first procedure. One patient was lost to follow-up after undergoing repeat SRS. In 9 of 18 patients, MR imaging or angiography confirmed total obliteration at a median post-SRS time of 40 months (95% CI 28.87-51.73 months). In 1 of 4 patients with a residual AVM, a third SRS was performed 55 months later. A fourth SRS was conducted in 2 patients, 1 of whom had obliteration confirmed on angiography 35.3 months later. After one or more radiosurgical procedures, complete obliteration was confirmed in 89 patients (67%). After a second SRS, a visual field defect due to an ARE developed in 1 patient and a transient hemiparesis developed in 2 patients. One patient underwent surgical evacuation of a hematoma 6 months after SRS. An illustrative case of AVM total obliteration is shown (Fig. 4) .
Discussion
Approximately 10% of cerebral AVMs are located in the basal ganglia and thalamus. 6, 13, 38 Intracranial hemorrhage is often associated with significant neurological morbidity in such deep-seated AVMs. In the absence of treatment, the overall risk of a spontaneous hemorrhage from a cerebral AVM appears to range from 2% to 5% per year. 3, 4, 12, 27 The presentation of hemorrhage from basal ganglia and thalamus AVMs varies from 72% to 91% of patients. 10, 24, 35 In the present series, 85% of patients with basal ganglia and thalamus AVMs had prior hemorrhage. Da Costa et al. 8 reported that a hemorrhagic presentation was a significant independent predictor of future AVM bleeding (annual rate of bleeding 7.5%, HR 2.15, p < 0.01).
Craniotomy and complete resection should be considered to be a potentially definitive treatment whenever the size and location of the AVM warrants that option. However, AVMs of the basal ganglia and thalamus are often considered to have excessive surgical risks. 7, 9, 13, 15, 20, 35 Gross et al. 13 reviewed the outcomes of resection for AVMs of the basal ganglia and thalamus. They noted an overall complete resection rate of 91% and a mortality rate of 2.4%. Among various reports, the overall significant morbidity rate varied from 13% to 33%. 9, 13, 35, 39 Embolization can be used alone or in combination with resection or SRS to treat AVMs. Embolization alone can completely obliterate relatively few AVMs and is also associated with significant management-related morbidity. 11, 26, 28, 36 In our literature survey we found that the published permanent morbidity rate after embolization for basal ganglia and thalamus AVMs varied between 11% and 40%. 15, 28, 35 
Confirmation of AVM Obliteration
Although we concur that cerebral angiography is the best method to confirm complete obliteration of an AVM, it is has proved difficult to obtain angiographic studies in some patients after SRS. The reasons are multiple but include patient satisfaction with MR imaging's correlation with angiographic obliteration (> 90%), the diverse geographic origin of our patient population, and patient unwillingness to undergo yet one more angiography session despite its small (< 1%) risk of a neurological event afterward. To determine the value of MR imaging, Pollock et al. 32 reported that the uncorrected positive predictive value of MR imaging was 84%. They also noted that in selected patients angiography showed only a persistent early draining vein. When such patients underwent repeat angiography 6-12 months later, even the early draining vein had resolved. After correcting for this additional data, the overall predictive value of MR imaging obliteration rose to 97%.
In the present study, both MR imaging and angiographic data were included. It would also be optimal to have all patients undergo follow-up angiography 3-5 years after repeat radiosurgery. The potential slight overestimation of obliteration rates associated with MR imaging are balanced by the tendency to underestimate long-term obliteration rates based only on early follow-up examinations. We believe it is both reasonable and necessary to use MR imaging evidence of obliteration to evaluate the outcomes of repeat SRS, although we continue to report the outcomes of SRS using both MR imaging and angiographic criteria. The timing of documentation of obliteration is variable since patients may have delayed imaging performed months to years after the requested time of 3 years.
In previous reports, the obliteration rates of AVMs in the basal ganglia and thalamus varied from 66% to 86% at 4 or 5 years, and the rates of permanent morbidity varied from 4% to 17% (Table 6) . 1, 18, 19, 25, 33, 35 Pollock et al. 33 reported that total obliteration of AVMs in the basal ganglia (10 cases), thalamus (30 cases), and brainstem (16 cases) was achieved in 24 (43%) of 56 patients after primary SRS at a median of 45 months. The actuarial rate of an AVM cure (including those confirmed by both angiography and MR imaging) after one or more radiosurgical procedures was 47% and 66% at 3 and 4 years after radiosurgery, respectively. In the present series, radiosurgery obliteration rates after a single procedure were 57% and 70% at 3 and 4 years, respectively. Koga et al. 19 reported that their 5-year total obliteration rate of thalamic AVMs was 82%. Higher total obliteration rates were found in patients who had sustained a prior hemorrhage and in those who were treated after the development of modern imaging and dose-planning techniques. In the present series, higher total obliteration rates were noted in patients with a prior hemorrhage and those with a smaller nidus volume, as well as in those who received a higher margin dose with fewer isocenters. The use of fewer isocenters is possible in patients with a more compact AVM nidus and more easily defined angioarchitecture. Our data suggest that larger volume AVMs may need multimodality management, including repeat SRS for lesions that are still patent within 3-4 years of the initial procedure. We generally consider prospectively staged SRS for AVM volumes exceeding 10 cm 3 . In cases involving smaller volumes, we prefer a single procedure, but we believe that a sufficiently effective marginal dose (for example, ≥ 17 Gy) must be delivered. We continue to evaluate the potential value of AVM embolization prior to SRS. In most cases, permanent embolization-induced volume reduction has been difficult to achieve, although flow reduction is often possible. With newer catheter techniques and agents such as Onyx, more complete and permanent volumetric reduction by embolization may improve the results of combined embolization and SRS. Alternatively, embolization after SRS may be a strategy that has greater merit, since the target definition will not be degraded by intranidal embolization artifacts. We hypothesize that postradiosurgery flow reduction will enhance the rapidity and completeness of AVM obliteration.
Corrected Versus Uncorrected Obliteration Times
When we calculated obliteration rates using either MR imaging or angiographic follow-up data, we found that obliteration rates varied by only a few percentage points in a comparison between corrected and uncorrected methodologies. The 4-year obliteration rate was slightly elevated from 65% to 70% and the 10-year obliteration rate was reduced slightly (from 76% to 72%). We believe that the actuarial calculations for AVM obliteration, as defined by MR imaging or angiography using corrected obliteration methods, provides the most accurate portrayal of AVM obliteration within this patient population. The magnitude of the effect of using uncorrected obliteration rates defined by angiography alone was more pronounced and raised the 5-and 10-year obliteration rates from 64% to 67%.
Hemorrhage After SRS
Arteriovenous malformations of the basal ganglia and thalamus more frequently present with hemorrhage * BG = basal ganglia; BS = brainstem; FU = follow-up; GK = Gamma Knife; Pts = patients; TH = thalamus. † Reflects the mean rather than the median value. ‡ Four-year total obliteration rate. § Five-year total obliteration rate.
than AVMs in other locations. 10, 24, 35 Fleetwood et al. 10 reported the natural history of AVMs of the basal ganglia and thalamus. During a 15-year period, 72% of patients with AVMs of the basal ganglia and thalamus presented with a hemorrhage and 86% of patients with hemorrhage developed either hemiparesis or hemiplegia. In their conservative management series (> 500 patient-years), the annual risk of hemorrhage was 9.8%. Patients with AVMs remain at risk for hemorrhage during the latency interval between SRS and total obliteration. The annual risk of hemorrhage after SRS for basal ganglia and thalamus AVMs ranges from 0% to 9.5% during the 1st year after SRS. In the 2nd year post-SRS, the annual risk of hemorrhage lessened but varied from 0% to 4.7% (Table 6 ). In the present series, the annual hemorrhage rate in the 1st year after SRS was 6.3%, but in the 2nd year it was 2.1%. Four of 17 observed hemorrhages during the latency period occurred after 3 years. When we removed from this analysis 5 patients with 7 hemorrhages occurring earlier than 6 months after SRS, the annual hemorrhage rate decreased to 2.7%. Several authors have suggested that their data project a decreasing hemorrhage risk after SRS. 16, 23 Although an increasing number of AVMs become obliterated over time, we are reluctant to conclude that subtotal obliteration significantly reduces bleeding risks. In view of the residual annual risk (4.7%) of hemorrhage in patients with incompletely obliterated AVMs, we believe that the goal of SRS remains complete AVM closure. Subtotal obliteration in this experience did not change the anticipated annual hemorrhage rate.
In the present series using multivariate analysis, a lower margin dose was associated with a lower rate of total obliteration, but it was not associated with a change in the rate of hemorrhage after SRS. Larger volume AVMs had a higher rate of hemorrhage after SRS, but there was no statistical difference in obliteration rates (Table 4) . The lower rate of total obliteration in AVMs that received lower margin doses may influence the observed hemorrhage rate. Since 25% of the observed hemorrhages in our series occurred 3 years or more after SRS, we believe that additional management, including repeat SRS, should be implemented if the AVM remains patent at that time. In this series, only 20 patients (15%) had not previously suffered a hemorrhage. Because of the high morbidity rate associated with an initial hemorrhage from a thalamic or basal ganglia hemorrhage, we believe that SRS should be considered even in patients who have not previously suffered a hemorrhage. In this series the presence or absence of a prior hemorrhage had no effect on the eventual obliteration rate, the hemorrhage rate, or the complication rate.
Complications of SRS
The risk of a radiation injury resulting in a permanent neurological deficit varies between 4% and 11.9% in most reports of SRS for AVMs of the basal ganglia and thalamus. 1, 18, 19, 25, 33, 35 In the present series, 6 patients (4.5%) developed permanent neurological deficits (hemiparesis in each case) due to AREs. Seven additional patients (5.3%) experienced temporary neurological symptoms or signs related to suspected AREs. We found that several factors were associated with a higher rate of symptomatic AREs: an AVM located in the thalamus (p = 0.041), a larger target volume (p < 0.0005), larger 12-Gy treatment volume (p = 0.001), larger maximum diameter (p < 0.0005), higher margin dose (p = 0.016), and a higher Pollock-Flickinger score (p = 0.008).
Delayed cyst formation or an expanding hematoma in the AVM bed after SRS is an uncommon but well-described phenomenon. 17, 30, 41 In the present series, a single patient who had sustained a hemorrhage before radiosurgery developed a delayed AVM bed cyst. This patient required no additional management.
Conclusions
Fifteen patients experienced a hemorrhage after SRS and 7 died of hemorrhage, defining a total mortality rate of 5.3% during the latency period after SRS. By 5 years after a single procedure, 72% of patients had complete AVM obliteration based on angiography and MR imaging criteria. More than half the patients who underwent repeat SRS had total obliteration at follow-up. Because of the irregular timing of both MR imaging and confirmatory angiography, we cannot project the precise time when AVM obliteration occurs. Our data suggest that 3 years after the initial SRS remains a reasonable time to contemplate additional management if the AVM remains patent. The annual bleeding rate was 4.4% during the latency interval until obliteration occurred. Hemorrhage did not occur after MR imaging or angiography confirmed no residual AVM. Six patients (4.5%) had a permanent neurological deficit after SRS. Temporary neurological deficits due to ARE were detected in 5.3%. We believe that SRS has an important clinical role in AVMs of lesions of the basal ganglia and thalamus that are deemed to involve excessive risks for craniotomy and surgical removal. The best candidates for SRS are patients with AVMs of the basal ganglia and patients with a smaller volume AVM eligible to receive at least 20 Gy at its margin.
